On Friday, Midstates Petroleum Company Inc (NYSE:MPO)’s shares declined -6.03% to $1.09.
Midstates Petroleum Company Inc (MPO) declared the closing of the formerly declared sale of ownership interest in developed and undeveloped acreage in the Dequincy area located in Beauregard and Calcasieu Parishes, Louisiana for $44 million to Pintail Oil and Gas LLC.
The net proceeds were about $42 million, which was net of customary closing adjustments. The proceeds from the sale will be used to pay down a portion of the outstanding borrowings under the Company’s revolving credit facility and for general corporate purposes.
Midstates Petroleum Company, Inc. engages in the exploration, development, and production of oil, natural gas liquids, and natural gas in the United States. It primarily focuses on oilfields in the Mississippian Lime trend in northwestern Oklahoma; the Anadarko Basin in Texas and Oklahoma; and the Upper Gulf Coast Tertiary trend in central Louisiana.
Tyco International plc (Ireland) Ordinary Share (NYSE:TYC)’s shares dropped -5.99% to $40.04.
Tyco International plc Ordinary Share (TYC) stated $0.43 in GAAP diluted earnings per share (EPS) from ongoing operations for the fiscal second quarter of 2015 and diluted EPS from ongoing operations before special items of $0.55. Revenue of $2.4 billion in the quarter reduced 2% as compared to the preceding year due to a 6% negative impact of the stronger U.S. dollar against foreign currencies. Organic revenue grew 2% in the quarter, led by Global Products with a 7% enhance. Installation revenue grew 1% organically and service revenue was relatively flat. Acquisitions contributed 2 percentage points of growth.
Tyco Chief Executive Officer George R. Oliver stated that they continued to deliver strong profitability in the second quarter, with earnings per share growing 17% year over year before special items and segment operating margin improving 50 basis points on a normalized basis. Not taking into account the impact of foreign currency exchange rates, they grew revenue 4% in the quarter through a combination of organic growth and acquisitions.
Tyco International Ltd. designs, sells, installs, and services security, fire detection, suppression, and life safety products worldwide. It operates in three segments: North America Installation & Services, Rest of World Installation & Services, and Global Products.
At the end of Friday’s trade, North Atlantic Drilling Ltd. (NYSE:NADL)‘s shares dipped -5.92% to $1.43.
North Atlantic Drilling Ltd. (NADL) declared that it has filed its annual report on Form 20-F for the year ended December 31, 2014. The Annual Report on Form 20-F is accessible from our website www.nadlcorp.com | Investor relations | Financial reports.
The Company’s Annual Report on Form 20-F, may be accessed through the website of the U.S. Securities and Exchange Commission - www.sec.gov. Shareholders may also request a hard copy of the Annual Report, which comprises the Company’s complete 2014 audited merged financial statements, free of charge, by sending an email to: [email protected].
North Atlantic Drilling Limited operates as an offshore drilling services contractor in the North Atlantic region. The company provides harsh environment offshore drilling services to the oil and gas industry primarily in Norway and the United Kingdom.
Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), ended its Friday’s trading session with -5.85% loss, and closed at $6.03.
Progenics Pharmaceuticals, Inc. (PGNX) and Valeant Pharmaceuticals International, declared that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending a new indication for RELISTOR® (methylnaltrexone bromide) Subcutaneous Injection for the treatment of opioid-induced constipation (OIC) when response to laxative therapy has not been sufficient in adult patients, aged 18 years and older. Additionally, the Committee has recommended a one-year extension of data/marketing protection for RELISTOR, to 11 years from the date of approval, citing the fact that RELISTOR offers a major contribution to patient care in comparison to existing therapies.
The CHMP is responsible for reviewing medicinal product applications for safety, quality and efficacy. The CHMP’s positive opinion on RELISTOR will be reviewed by the European Commission, which has the authority to approve medicines for the European Union. The final decision will be applicable to all 28 European Union member countries plus Iceland and Norway.
Progenics Pharmaceuticals, Inc. develops medicines for oncology in the United States and internationally. The company’s primary clinical-stage product candidates comprise prostate specific membrane antigen (PSMA) antibody-drug conjugate, which has accomplished Phase II testing in chemotherapy-practiced patients and is ongoing second cohort in chemotherapy-naïve patients for the treatment of prostate cancer; 1404, a radio-labeled small molecule that has accomplished Phase II testing, in addition to acts as an imaging agent to diagnose and detect prostate cancer; and Azedra, a radiotherapeutic product candidate, which is in Phase IIb registrational trial under special protocol assessment for the treatment of pheochromocytoma and paraganglioma.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
